Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lydia Roy

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Nature Reviews. Clinical Oncology|November 28, 2009
Hematology: dasatinib regimens for patients with chronic myeloid leukemiaFrançois Guilhot, Lydia Roy
Current Opinion in Hematology|January 10, 2012
Current treatment strategies in chronic myeloid leukemiaFrançois Guilhot, Lydia Roy, Cécile Tomowiak
Hematology/Oncology Clinics of North America|July 24, 2004
Interferon therapy in chronic myelogenous leukemiaFrançois Guilhot, Lydia Roy, Joëlle Guilhot, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Interferon in chronic myeloid leukaemia: past and futureFrançois Guilhot, Lydia Roy, Pierre-Jean Saulnier, et al.
Leukemia & Lymphoma|September 2, 2022
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?Alice Canon, Lydia Roy, Xavier Chevalier, et al.
Clinical Lymphoma & Myeloma|March 27, 2007
Immunotherapy in chronic myelogenous leukemiaFrançois Guilhot, Lydia Roy, Geraldine Martineua, et al.
Leukemia & Lymphoma|April 10, 2008
Immunotherapeutic approaches in chronic myelogenous leukemiaFrançois Guilhot, Lydia Roy, Pierre-Jean Saulnier, et al.
Scientific Reports|February 26, 2020
Innate T-αβ lymphocytes as new immunological components of anti-tumoral "off-target" effects of the tyrosine kinase inhibitor dasatinibAlice Barbarin, Myriam Abdallah, Lucie Lefèvre, et al.
American Journal of Medical Genetics|January 25, 2002
PRINS, the other in situ DNA labeling method useful in cellular biologyPhilippe Coullin, Lydia Roy, Franck Pellestor, et al.
Surgery|September 19, 2017
Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomyNicola de'Angelis, Solafah Abdalla, Vincenzo Lizzi, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Nature Reviews. Clinical Oncology|November 28, 2009
Hematology: dasatinib regimens for patients with chronic myeloid leukemiaFrançois Guilhot, Lydia Roy
Current Opinion in Hematology|January 10, 2012
Current treatment strategies in chronic myeloid leukemiaFrançois Guilhot, Lydia Roy, Cécile Tomowiak
Hematology/Oncology Clinics of North America|July 24, 2004
Interferon therapy in chronic myelogenous leukemiaFrançois Guilhot, Lydia Roy, Joëlle Guilhot, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Interferon in chronic myeloid leukaemia: past and futureFrançois Guilhot, Lydia Roy, Pierre-Jean Saulnier, et al.
Leukemia & Lymphoma|September 2, 2022
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?Alice Canon, Lydia Roy, Xavier Chevalier, et al.
Clinical Lymphoma & Myeloma|March 27, 2007
Immunotherapy in chronic myelogenous leukemiaFrançois Guilhot, Lydia Roy, Geraldine Martineua, et al.
Leukemia & Lymphoma|April 10, 2008
Immunotherapeutic approaches in chronic myelogenous leukemiaFrançois Guilhot, Lydia Roy, Pierre-Jean Saulnier, et al.
Scientific Reports|February 26, 2020
Innate T-αβ lymphocytes as new immunological components of anti-tumoral "off-target" effects of the tyrosine kinase inhibitor dasatinibAlice Barbarin, Myriam Abdallah, Lucie Lefèvre, et al.
American Journal of Medical Genetics|January 25, 2002
PRINS, the other in situ DNA labeling method useful in cellular biologyPhilippe Coullin, Lydia Roy, Franck Pellestor, et al.
Surgery|September 19, 2017
Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomyNicola de'Angelis, Solafah Abdalla, Vincenzo Lizzi, et al.
Pageof 7